

12,89 billion	72	11,24 billion doses	92%	404	4.8 billion
Approved Vaccines Production	Vaccine Producing manufacturing sites	Total signed country deals	Transport Temperature +2 to +8 °C	Ongoing Clinical Trials vaccine candidates	Global population with at least 1 vaccine

Last updated 30 July 2021

[Source link](#)

Welcome


4.8 billion doses have been administered worldwide and about 35 million doses per day are being administered. To date, approximately 24% of the world's population is reported to be fully vaccinated and 31.8% have received at least one dose. We are seeing a higher vaccination rate in developed economies such as the United States and France. However, the rate of vaccination in these developed economies seemed to be stagnating. In comparison, developing economies are currently very low in terms of the vaccination rate per capita. According to the latest reports only 1.3% in low-income countries have been vaccinated. This means that a strong catch up is needed in these countries.

The third booster injection is being announced in several countries as a response to the spread of the Delta variant. This would lead to higher distribution volumes of the COVID-19 vaccines. In parallel, several governments have imposed the rule of having the vaccine passport becoming part of the safe travel regulations.

In India, despite being a vaccine producer, they have encountered challenges in reaching their vaccination targets. On the other hand, countries like China are at the top of the league in terms of vaccinating the population.

Glyn Hughes & Frank Van Gelder

Updates on the Covid-19 vaccine global production

Company name	Vaccine name	Production sites	Approved production	Signed deals	Approved countries	Vaccine type	Doses
 AstraZeneca	AZD1222	16	2,1 Billion	2.869.265.000	120	Non Replicating Viral Vector	2
 BIONTECH Pfizer	BNT162b2	8	3 Billion	3.104.570.075	97	mRNA	2
 moderna	mRNA - 1273	7	800 Million	1.340.000.000	65	mRNA	2
 SINOPHARM	BBIBP-CorV (Beijing)	3	1 Billion	148.038.000	59	Inactivated	2
 THE GAMALEYA NATIONAL CENTER OF EPIDEMIOLOGY AND MICROBIOLOGY	Sputnik V	6	390 Million	445.987.500	70	Non Replicating Viral Vector	2
 CanSinoBIO	Ad5-nCoV	4	500 Million	76.800.000	8	Non Replicating Viral Vector	2
 SERUM INSTITUTE OF INDIA PVT. LTD.	Covishield	1	200 Million	100.000.000	45	Non Replicating Viral Vector	2
 BHARAT BIOTECH	Covaxin	3	494,2 Milion	278.500.000	9	Inactivated	2
 janssen Johnson & Johnson	Ad26.COV2.S	8	1 Billion	851.100.000	59	Non Replicating Viral Vector	1
 sinovac	Coronavac	4	1,75 Billion	916.023.000	39	Inactivated	2
 Z-F-SW INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES	RBD-Dimer	1	1 Million	0	2	Protein Subunit	2
 BEKTAP	EpiVacCorona	1	5 Million	0	2	Protein Subunit	2
 BAKALBIA KOPCHABAYPICHAN	KoviVac	1	3 Million	0	1	Inactivated	2
 RIISP Research Institute for Biological Safety Problems	QazCovid-in	1	4 Million	0	1	Inactivated	2
 MINHAI 民海生物 MINHAI BIOTECHNOLOGY CO., LTD.	SARS-CoV-2 Vaccine (Vero Cells)	1	1 Million	0	1	Inactivated	2
 Shafa Pharmed Pars	Covid-19	1	1 Million	0	1	Inactivated	1
 IGEE International Centre for Genetic Engineering and Biotechnology Developing Knowledge	CIGB-66	1	500.000	0	1		2
 THE GAMALEYA NATIONAL CENTER OF EPIDEMIOLOGY AND MICROBIOLOGY	Sputnik Light	6	500.000	0	12	Non Replicating Viral Vector	2
 MVC 高維疫苗生物製劑股份有限公司 MEDIGEN VACCINE BIOLOGICS CO	MVC-COV1901	1	500.000	0	1	Protein Subunit	2

[Source link](#)

Hot from the needle

1st International Pharma Logistics Masterclass
where business meets academics
 September 7th until September 11th, 2021
[Register now!](#)

Key Challenges

Innovative Forum

Academic & Industry Insights

Best practices & Network

University of Antwerp
 City Campus,
 Antwerp Belgium

For more information
[Click here](#)

Presentations, debates & practical workshops for industry professionals and master students

Broadening industry experience together with supply chain experts

Sharing knowledge & insights in an international framework

Academic theory combined with strategic decision making and operational insights

METRANS
 Transportation Consortium
 US FOCUS

PHARMA
 AERO

University of Antwerp

US trying to help India, others to produce Covid-19 vaccine: ...

The Times of India - Aug 4, 2021

[Read the full article](#)

Pfizer and Moderna raise prices for COVID-19 vaccines in EU

EURACTIV.com - Aug 2, 2021

[Read the full article](#)

UK to offer COVID-19 vaccine booster shots for 32m from September: Report

GULF Nation - Aug 2, 2021

[Read the full article](#)

Full US Approval for Pfizer's Covid Vaccine Expected by Early September: Report

News 18 - Aug 4, 2021

[Read the full article](#)

Negative test for anyone wanting to enter Germany without full vaccination

The Portugal news - Aug 2, 2021

[Read the full article](#)

New York to become first major US city to require vaccination proof for indoor activities: COVID-19 updates

USA TODAY - Aug 2, 2021

[Read the full article](#)

Vaccine clinical trial updates

Protein Subunit					
FINLAY-FR-1	Recombinant Protein	UB-612	FINLAY-FR-2	NVX-CoV2373	Nanocovax
Instituto Finlay de Vacunas Cuba	Sonofi/GSK	COVAXX	Instituto Finlay de Vacunas Cuba	Novavax	Nanogen
4 trials in 1 country	4 trials in 2 countries	4 trials in 1 country	3 trials in 1 country	5 trials in 6 countries	3 trials in 1 country
Protein Subunit		DNA			RNA
Recombinant (Sf9 cell)	COVOVAX	AG0302-COVID19	INO-4800	ZyCoV-C	CVnCoV
West China Hospital	Serum institute of India	AnGes	Inovio	Zyklus Cadila	Curevac
5 trials in 1 country	2 trials in 1 country	4 trials in 1 country	6 trials in 3 countries	5 trials in 1 country	5 trials in 4 countries
RNA		Non Replicating Viral Vector			VLP
BNT162b1	mRNA	mRNA-1273.211	GRAd-COV2	AZD2816	Plant-based VLP
Pfizer/BioNTech	Walvax	Moderna	ReiThera	Oxford/AstraZeneca	Medicago
5 trials in 3 countries	4 trials in 1 country	2 trials in 1 country	5 trials in 12 countries	2 trials in 2 countries	3 trials in 2 countries
Inactivated					
Inactivated (Vero Cells)	VLA2001				
Chinese Academy of Medical Sciences	ValNeva				
5 trials in 3 countries	3 trials in 1 country				

Last updated 30 July 2021


[Source link](#)

Global vaccine administration progress

COVID-19 vaccine doses administered

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses can be higher than the number of people in the population.

Our World
in Data



Total: 4.8 billion


[Source link](#)

Source: Official data collated by Our World in Data – Last updated 3 August 2021, 09:00 (London time) OurWorldInData.org/coronavirus • CC BY

Share of the population fully vaccinated against COVID-19

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

Our World
in Data




Source: Official data collated by Our World in Data – Last updated 3 August 2021, 09:00 (London time) OurWorldInData.org/coronavirus • CC BY
Note: This data is only available for countries which report the breakdown of doses administered by first and second doses. Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

[Source link](#)

Number of people fully vaccinated against COVID-19

Total number of people who received all doses prescribed by the vaccination protocol.


Our World
in Data



Source: Official data collated by Our World in Data – Last updated 3 August 2021, 09:00 (London time) OurWorldInData.org/coronavirus • CC BY
Note: This data is only available for countries which report the breakdown of doses administered by first and second doses. Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

[Source link](#)

Production forecast 2021



China 3.988.000.000

Sinovac	2.013.000.000
Sinopharm	1.000.000.000
CanSinoBio	500.000.000
ZFSW	375.000.000
AstraZeneca	100.000.000

India 1.782.250.000

AstraZeneca	886.250.000
Bahrat BioTech	570.000.000
SIOI	200.000.000
GNC	126.000.000

US 2.520.000.000

BioTech Pfizer	1.000.000.000
Moderna	1.000.000.000
AstraZeneca	420.000.000
Bharat BioTech	100.000.000

Belgium 1.125.000.000

BioTech Pfizer	1.125.000.000
----------------	---------------

Australia 50.000.000

AstraZeneca	50.000.000
-------------	------------

Brazil 265.500.000

AstraZeneca	163.500.000
GNC	56.000.000
Sinovac	46.000.000

Egypt 60.300.000

Sinovac	60.300.000
---------	------------

France 108.000.000

Johnson&Johnson	108.000.000
-----------------	-------------

Germany 1.046.000.000

BioTech Pfizer	1.000.000.000
GNC	36.000.000
AstraZeneca	10.000.000

Indonesia 250.000.000

Sinovac	250.000.000
---------	-------------

Italy 25.000.000

Johnson&Johnson	25.000.000
-----------------	------------

Japan 30.000.000

AstraZeneca	30.000.000
-------------	------------

Kazakhstan 5.640.000

GNC	5.640.000
-----	-----------

Malaysia 12.035.000

Sinovac	12.000.000
CanSinoBio	35.000

Mexico 285.000.000

AstraZeneca	250.000.000
CanSinoBio	35.000.000

Netherlands 692.000.000

Johnson&Johnson	692.000.000
-----------------	-------------

Pakistan 21.000

CanSinoBio	21.000
------------	--------

South Africa 150.000.000

Johnson&Johnson	150.000.000
-----------------	-------------

South Korea 250.000.000

GNC	150.000.000
Moderna	100.000.000

Spain 85.000.000

Moderna	60.000.000
Johnson&Johnson	25.000.000

Switzerland 50.000.000

BioTech Pfizer	50.000.000
----------------	------------

Thailand 61.000.000

AstraZeneca	61.000.000
-------------	------------

UAE 150.000.000














Sinopharm	150.000.000
-----------	-------------

UK 562.500.000

AstraZeneca	562.500.000
-------------	-------------

Source link

Supply chain insights

Company name	Vaccine name	Product temperature	Transport temperature
 AstraZeneca	AZD1222	+2C° to +8C°	+2C° to +8C°
 BIONTECH Pfizer	BNT162b2	-70C°	+15C° to +25C°
 moderna™ messenger therapeutics	mRNA - 1273	-20C°	+2C° to +8C°
 SINOPHARM	BBIBP-CorV (Beijing)	+2C° to +8C°	+2C° to +8C°
 THE GAMALEYA NATIONAL CENTER OF EPIDEMIOLOGY AND MICROBIOLOGY	Sputnik V	+2C° to +8C°	+2C° to +8C°
 CanSinoBIO	Ad5-nCoV	+2C° to +8C°	+2C° to +8C°
 SERUM INSTITUTE OF INDIA PVT. LTD. Cytos Biotechnologies Group	Covishield	+2C° to +8C°	+2C° to +8C°
 BHARAT BIOTECH	Covaxin	+2C° to +8C°	+2C° to +8C°
 janssen PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON	Ad26.COV2.S	-20C°	+2C° to +8C°
 sinovac	Coronavac	+2C° to +8C°	+2C° to +8C°
 Z-FSW INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES	RBD-Dimer	+2C° to +8C°	+2C° to +8C°
 BEKTUP	EpiVacCorona	+2C° to +8C°	+2C° to +8C°
 KoviVac	KoviVac	+2C° to +8C°	+2C° to +8C°
 RIBSP Research Institute for Biological Safety Problems	QazCovid-in	+2C° to +8C°	+2C° to +8C°
 MINHAI 民海生物 MINHAI BIOTECHNOLOGY CO., LTD.	SARS-CoV-2 Vaccine (Vero Cells)	+2C° to +8C°	+2C° to +8C°
 Shafa Pharmad Pars	Covid-19	+2C° to +8C°	+2C° to +8C°
 IGEB International Centre for Genetic Engineering and Biotechnology Developing Knowledge	CIGB-66	+2C° to +8C°	+2C° to +8C°
 THE GAMALEYA NATIONAL CENTER OF EPIDEMIOLOGY AND MICROBIOLOGY	Sputnik Light	+2C° to +8C°	+2C° to +8C°
 MVC 高福成苗生物製劑股份有限公司 MEDIGEN VACCINE BIOLOGICS CO	MVC-COV1901	+2C° to +8C°	+2C° to +8C°

[Source link](#)

On Course for the Future The 2+2 on Innovation in Logistics

March 22–25, 2022
San Francisco, USA



Executive
Summit



Contact details

www.pharma.aero
secgen@pharma.aero

www.tiaca.org
secretariat@tiaca.org

www.4advice.eu
info@4advice.eu

Authors:
4Advice
Pharma.Aero
TIACA

This publication contains general information only and Pharma.Aero and TIACA are not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Pharma.Aero and TIACA shall not be responsible for any loss sustained by any person who relies on this publication.



Copyright © 2021 Pharma.Aero and TIACA. All rights reserved